Glycopyrronium Bromide

CHEMBL1201027 Phase 4 Approved Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
398.3 g/mol
LogP
Phase
4

An anticholinergic bronchodilator used as a maintenance treatment for chronic obstructive pulmonary disease to reduce airway constriction by blocking muscarinic receptors in the lungs. The inhaled formulation provides long-acting bronchodilation to improve airflow and reduce breathlessness throughout the day. It does not provide immediate symptom relief during an acute attack.

Molecular Weight

398.3000 g/mol

TPSA

46.50 Ų

Therapeutic Areas

Mechanism of Action

Activates beta-2 adrenergic receptors on bronchial smooth muscle, stimulating adenylyl cyclase and increasing intracellular cAMP. This relaxes airway smooth muscle and produces bronchodilation.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mechanism

Activates beta-2 adrenergic receptors on bronchial smooth muscle, stimulating adenylyl cyclase and increasing intracellular cAMP. This relaxes airway smooth muscle and produces bronchodilation.

2D Structure

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

C[N+]1(C)CCC(OC(=O)C(O)(c2ccccc2)C2CCCC2)C1.[Br-]

InChI

InChI=1S/C19H28NO3.BrH/c1-20(2)13-12-17(14-20)23-18(21)19(22,16-10-6-7-11-16)15-8-4-3-5-9-15;/h3-5,8-9,16-17,22H,6-7,10-14H2,1-2H3;1H/q+1;/p-1

Molecular Formula

C19H28BrNO3

HBD / HBA

1 / 4

Rotatable Bonds

5

Heavy Atoms

24

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Frequently Asked Questions

An anticholinergic bronchodilator used as a maintenance treatment for chronic obstructive pulmonary disease to reduce airway constriction by blocking muscarinic receptors in the lungs. The inhaled formulation provides long-acting bronchodilation to improve airflow and reduce breathlessness throughout the day. It does not provide immediate symptom relief during an acute attack.

Activates beta-2 adrenergic receptors on bronchial smooth muscle, stimulating adenylyl cyclase and increasing intracellular cAMP. This relaxes airway smooth muscle and produces bronchodilation.

Yes, Glycopyrronium Bromide is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201027. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 11693. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Medical Disclaimer

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.